Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular

of cyclic guanosine monophosphate. Modified-release dipyridamole has a marketing authorisation for the 'secondary prevention of ischaemic stroke and transient ischaemic attacks either alone or in conjunction with aspirin'. It is available either on its own as Persantin Retard, or in a combination tablet with aspirin as Asasantin Retard. 3.5 Dipyridamole has activity as a vasodilator; therefore, it should be used with caution in people with severe coronary artery disease, including unstable angina and/or recent myocardial infarction, left ventricular outflow obstruction or haemodynamic instability (for example, decompensated heart failure). For full details of side effects and contraindications, see the summary of product characteristics. 3.6 The cost of treatment for 30 days with modified-release dipyridamole alone is £7.50 and modified-release dipyridamole plus aspirin is £7.79 per person (BNF, edition 60). Costs may vary in different settings because of negotiated procurement discounts. 4 Evidence and interpretation The Appraisal Committee considered evidence from a number of sources. 4.1 Clinical effectiveness 4.1.1 Four randomised controlled trials (RCTs) were identified by the Assessment Group. Two of these were included in the previous NICE technology appraisal guidance 90 (CAPRIE and ESPS-2) and 2 were published later (ESPRIT and PRoFESS). The RCTs were considered by the Assessment Group
